Show simple item record

dc.contributor.authorJiyad, Z
dc.contributor.authorOlsen, C
dc.contributor.authorBurke, M
dc.contributor.authorIsbel, N
dc.contributor.authorGreen, Adèle C
dc.date.accessioned2016-06-24T12:05:15Z
dc.date.available2016-06-24T12:05:15Z
dc.date.issued2016-05-10
dc.identifier.citationAzathioprine and risk of skin cancer in organ transplant recipients: systematic review and meta-analysis. 2016: Am J Transplanten
dc.identifier.issn1600-6143
dc.identifier.pmid27163483
dc.identifier.doi10.1111/ajt.13863
dc.identifier.urihttp://hdl.handle.net/10541/614565
dc.description.abstractAzathioprine, a purine antimetabolite immunosuppressant, photosensitises the skin and causes the production of mutagenic reactive oxygen species. It is postulated to increase the risk of squamous cell carcinoma (SCC) and other skin cancers in organ transplant recipients (OTRs), but evidence from multiple, largely single-centre studies to date has been inconsistent. We aimed to resolve the issue of azathioprine's carcinogenicity by conducting a systematic review of the relevant literature and pooling published risk estimates to evaluate the risks of SCC, basal cell carcinoma (BCC), keratinocyte cancers (KC) overall, and other skin cancers, in relation to azathioprine treatment. 27 studies were included in total, with risk estimates from 13 of these studies able to be pooled for quantitative analysis. The overall summary estimate showed a significantly increased risk of SCC in relation to azathioprine exposure (1.56, 95% confidence interval, CI, 1.11-2.18). No significant associations between azathioprine treatment and BCC (0.96, 95% CI 0.66-1.40) or KC (0.84, 95% CI 0.59-1.21) risk were observed. There was significant heterogeneity between studies for azathioprine risk estimates and the outcomes of SCC, BCC and KC. The pooled findings of available evidence support the contention that treatment with azathioprine increases the risk of SCC in OTRs. This article is protected by copyright. All rights reserved.
dc.languageENGen
dc.language.isoenen
dc.rightsArchived with thanks to American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeonsen
dc.titleAzathioprine and risk of skin cancer in organ transplant recipients: systematic review and meta-analysis.en
dc.typeArticleen
dc.contributor.departmentCancer and Population Studies Group, QIMR Berghofer Medical Research Institute, Brisbane, Queenslanden
dc.identifier.journalAmerican Journal of Transplantationen
refterms.dateFOA2020-04-21T09:14:50Z
html.description.abstractAzathioprine, a purine antimetabolite immunosuppressant, photosensitises the skin and causes the production of mutagenic reactive oxygen species. It is postulated to increase the risk of squamous cell carcinoma (SCC) and other skin cancers in organ transplant recipients (OTRs), but evidence from multiple, largely single-centre studies to date has been inconsistent. We aimed to resolve the issue of azathioprine's carcinogenicity by conducting a systematic review of the relevant literature and pooling published risk estimates to evaluate the risks of SCC, basal cell carcinoma (BCC), keratinocyte cancers (KC) overall, and other skin cancers, in relation to azathioprine treatment. 27 studies were included in total, with risk estimates from 13 of these studies able to be pooled for quantitative analysis. The overall summary estimate showed a significantly increased risk of SCC in relation to azathioprine exposure (1.56, 95% confidence interval, CI, 1.11-2.18). No significant associations between azathioprine treatment and BCC (0.96, 95% CI 0.66-1.40) or KC (0.84, 95% CI 0.59-1.21) risk were observed. There was significant heterogeneity between studies for azathioprine risk estimates and the outcomes of SCC, BCC and KC. The pooled findings of available evidence support the contention that treatment with azathioprine increases the risk of SCC in OTRs. This article is protected by copyright. All rights reserved.


Files in this item

Thumbnail
Name:
552374.pdf
Size:
878.7Kb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record